Search

Your search keyword '"MIZUTANI, Hideaki"' showing total 39 results

Search Constraints

Start Over You searched for: Author "MIZUTANI, Hideaki" Remove constraint Author: "MIZUTANI, Hideaki" Language english Remove constraint Language: english
39 results on '"MIZUTANI, Hideaki"'

Search Results

2. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

5. Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

6. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)

7. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations

9. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

10. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

11. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.

12. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)

15. First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations.

16. MO1-1 LIGHT-NING 2nd interim analysis: Early safety of 1L nivolumab + ipilimumab +/- chemotherapy for NSCLC in Japan

18. Uncommon mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901).

20. 水制域における河床材料の粒度分布特性とそれらの環境関連性に関する研究

22. Observed Features of Langmuir Turbulence Forced by Misaligned Wind and Waves under Destabilizing Buoyancy Flux.

24. First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).

25. Numerical modelling of river embankment failure due to overtopping flow considering infiltration effects.

26. Epithelial to Mesenchymal Transition of Lung Cancer Cells.

27. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.

28. Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901).

29. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations.

30. Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report.

31. Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing.

32. Interstitial lung disease associated with amrubicin chemotherapy in patients with lung cancer: a single institutional study.

33. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.

34. Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer.

35. Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.

36. MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells.

37. HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent manner.

38. Anticancer drug clustering based on proteomic profiles and a sensitivity database in a lung cancer cell line panel.

39. The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: biological analyses for future clinical application.

Catalog

Books, media, physical & digital resources